29.01.2018 • News

Azelis and Tagra Biotechnologies Extend Partnership

Israel’s Tagra Biotechnologies has appointed Azelis as the exclusive...
Israel’s Tagra Biotechnologies has appointed Azelis as the exclusive distributor of its range of Release on Demand (RND) microcapsules for all personal care applications in France and Benelux (c) Jakub Pavlinec/Getty Image

Israel’s Tagra Biotechnologies has appointed Azelis as the exclusive distributor of its range of Release on Demand (RND) microcapsules for all personal care applications in France and Benelux, with immediate effect. This latest agreement builds on an existing partnership between the two companies in most of Europe as well as in Canada, China, India, Australia and New Zealand.

“Azelis is well placed to increase market penetration in France and Benelux, and Tagra’s patented technology for the encapsulation of actives, UV filters and pigments is a welcome addition to our portfolio to these markets,” said Tony Craske, market segment director of Azelis EMEA.

Tagra describes itself as a leader in RND microencapsulation technology, a method that allows the controlled/immediate release of non-water soluble ingredients, including actives, vitamins, essential oils, flavonoids, silicones, pigments and sunscreens.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read